Conference
Initial experience with yttrium 90 ibritumomab tiuxetan (Zevalin®):: A model for successful implementation of radioimmunotherapy (RIT) in the community setting.
Authors
Vansant JP; Divine RW; Begani PM; Berry RP; Seligman M; Weresch J; Ey FS
Volume
102
Pagination
pp. 307B-307B
Publisher
AMER SOC HEMATOLOGY
Publication Date
November 16, 2003
Name of conference
45th Annual Meeting of the American-Society-of-Hematology
Conference place
CALIFORNIA, SAN DIEGO
Conference start date
December 6, 2003
Conference end date
December 9, 2003
Conference proceedings
BLOOD
Issue
11
ISSN
0006-4971